Drug-induced　liver　injury　(DILI)　is　an　important　clinical　problem,　which　has　received　more　attention　in　recent　decades.　It　can　be　induced　by　small　chemical　molecules,　biological　agents,　traditional　Chinese　medicines　(TCM),　natural　medicines　(NM),　health　products　(HP),　and　dietary　supplements　(DS).　Idiosyncratic　DILI　is　far　more　common　than　intrinsic　DILI　clinically　and　can　be　classified　into　hepatocellular　injury,　cholestatic　injury,　hepatocellular-cholestatic　mixed　injury,　and　vascular　injury　based　on　the　types　of　injured　target　cells.　The　CSH　guidelines　summarized　the　epidemiology,　pathogenesis,　pathology,　and　clinical　manifestation　and　gives　16　evidence-based　recommendations　on　diagnosis,　differential　diagnosis,　treatment,　and　prevention　of　DILI.